Tag: Aquavit Pharmaceuticals

All

Aquavit Pharmaceuticals, Inc. has submitted to the U.S. FDA an Investigation of New Drug package for a new botulinum toxin, DTX-021.

A global survey of more than 12,000 consumers finds growing interest in personalized, multimodal approaches that evolve with patients’ goals.